Novo Nordisk CEO on Earnings, 2020 Outlook, Coronavirus

The transcript features an interview with the CEO of Nova Door Disc discussing 2020 earnings, the impact of coronavirus on operations, and the company's strategic response. The CEO highlights the transition from insulin dependence to growth opportunities with new drug categories. The discussion also covers the measures taken to ensure staff safety in China and the potential use of diabetes drugs in treating Alzheimer's. The CEO expresses optimism about the pharmaceutical industry's role in addressing the coronavirus outbreak.

What is the significance of the new drug category mentioned by the chief executive?

What are the company's expectations regarding the development of vaccines and medicines for the coronavirus?

How does the company plan to address the potential use of diabetes drugs in Alzheimer's treatment?